Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer

Tatsuhiro Kajitani, Akitaka Makiyama, Shuji Arita, Hozumi Shimokawa, Hisanobu Oda, Tsuyoshi Shirakawa, Eishi Baba, Taito Esaki

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Background/Aim: Readministration of antiepidermal growth factor receptor (EGFR) antibody for metastatic colorectal cancer (mCRC) after disease progression remains to be determined. Patients and Methods: Readministration of anti-EGFR antibody in mCRC patients previously refractory to anti-EGFR antibody was prospectively observed. Results: A total of thirteen patients with a median age of 60-years old and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled. The median number of previous chemotherapies was 3 (range 2-5). Prior anti-EGFR antibody in combination with cytotoxic drugs was administered in 12 patients. Anti-EGFR antibody readministration regimens were cetuximab/panitumumab plus capecitabine/S-1 (seven patients), panitumumab plus FOLFOX (three patients), cetuximab plus irinotecan (two patients), and panitumumab monotherapy (one patient). Seven patients showed stable disease following readministration and six patients showed progressive disease. The median overall survival (OS) following readministration was 228 days and the median PFS was 102 days. Patients with intervals longer than 90 days between anti-EGFR therapies exhibited more favorable survival than those with intervals shorter than 90 days. Switching of anti-EGFR antibody between treatments was observed to contribute survival. Conclusion: Anti-EGFR antibody readministration could show a modest survival benefit in mCRC patients, with the length of therapy interval and switching of antibody being important contributory factors.

元の言語英語
ページ(範囲)6459-6468
ページ数10
ジャーナルAnticancer Research
37
発行部数11
DOI
出版物ステータス出版済み - 11 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Antibodies
Anti-Idiotypic Antibodies
irinotecan
Survival
Growth Factor Receptors
Disease Progression
Therapeutics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Kajitani, T., Makiyama, A., Arita, S., Shimokawa, H., Oda, H., Shirakawa, T., ... Esaki, T. (2017). Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer. Anticancer Research, 37(11), 6459-6468. https://doi.org/10.21873/anticanres.12101

Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer. / Kajitani, Tatsuhiro; Makiyama, Akitaka; Arita, Shuji; Shimokawa, Hozumi; Oda, Hisanobu; Shirakawa, Tsuyoshi; Baba, Eishi; Esaki, Taito.

:: Anticancer Research, 巻 37, 番号 11, 01.11.2017, p. 6459-6468.

研究成果: ジャーナルへの寄稿記事

Kajitani, T, Makiyama, A, Arita, S, Shimokawa, H, Oda, H, Shirakawa, T, Baba, E & Esaki, T 2017, 'Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer', Anticancer Research, 巻. 37, 番号 11, pp. 6459-6468. https://doi.org/10.21873/anticanres.12101
Kajitani, Tatsuhiro ; Makiyama, Akitaka ; Arita, Shuji ; Shimokawa, Hozumi ; Oda, Hisanobu ; Shirakawa, Tsuyoshi ; Baba, Eishi ; Esaki, Taito. / Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer. :: Anticancer Research. 2017 ; 巻 37, 番号 11. pp. 6459-6468.
@article{b8e4b04cd86245e09faac2ea5fa7d7bf,
title = "Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer",
abstract = "Background/Aim: Readministration of antiepidermal growth factor receptor (EGFR) antibody for metastatic colorectal cancer (mCRC) after disease progression remains to be determined. Patients and Methods: Readministration of anti-EGFR antibody in mCRC patients previously refractory to anti-EGFR antibody was prospectively observed. Results: A total of thirteen patients with a median age of 60-years old and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled. The median number of previous chemotherapies was 3 (range 2-5). Prior anti-EGFR antibody in combination with cytotoxic drugs was administered in 12 patients. Anti-EGFR antibody readministration regimens were cetuximab/panitumumab plus capecitabine/S-1 (seven patients), panitumumab plus FOLFOX (three patients), cetuximab plus irinotecan (two patients), and panitumumab monotherapy (one patient). Seven patients showed stable disease following readministration and six patients showed progressive disease. The median overall survival (OS) following readministration was 228 days and the median PFS was 102 days. Patients with intervals longer than 90 days between anti-EGFR therapies exhibited more favorable survival than those with intervals shorter than 90 days. Switching of anti-EGFR antibody between treatments was observed to contribute survival. Conclusion: Anti-EGFR antibody readministration could show a modest survival benefit in mCRC patients, with the length of therapy interval and switching of antibody being important contributory factors.",
author = "Tatsuhiro Kajitani and Akitaka Makiyama and Shuji Arita and Hozumi Shimokawa and Hisanobu Oda and Tsuyoshi Shirakawa and Eishi Baba and Taito Esaki",
year = "2017",
month = "11",
day = "1",
doi = "10.21873/anticanres.12101",
language = "English",
volume = "37",
pages = "6459--6468",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer

AU - Kajitani, Tatsuhiro

AU - Makiyama, Akitaka

AU - Arita, Shuji

AU - Shimokawa, Hozumi

AU - Oda, Hisanobu

AU - Shirakawa, Tsuyoshi

AU - Baba, Eishi

AU - Esaki, Taito

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background/Aim: Readministration of antiepidermal growth factor receptor (EGFR) antibody for metastatic colorectal cancer (mCRC) after disease progression remains to be determined. Patients and Methods: Readministration of anti-EGFR antibody in mCRC patients previously refractory to anti-EGFR antibody was prospectively observed. Results: A total of thirteen patients with a median age of 60-years old and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled. The median number of previous chemotherapies was 3 (range 2-5). Prior anti-EGFR antibody in combination with cytotoxic drugs was administered in 12 patients. Anti-EGFR antibody readministration regimens were cetuximab/panitumumab plus capecitabine/S-1 (seven patients), panitumumab plus FOLFOX (three patients), cetuximab plus irinotecan (two patients), and panitumumab monotherapy (one patient). Seven patients showed stable disease following readministration and six patients showed progressive disease. The median overall survival (OS) following readministration was 228 days and the median PFS was 102 days. Patients with intervals longer than 90 days between anti-EGFR therapies exhibited more favorable survival than those with intervals shorter than 90 days. Switching of anti-EGFR antibody between treatments was observed to contribute survival. Conclusion: Anti-EGFR antibody readministration could show a modest survival benefit in mCRC patients, with the length of therapy interval and switching of antibody being important contributory factors.

AB - Background/Aim: Readministration of antiepidermal growth factor receptor (EGFR) antibody for metastatic colorectal cancer (mCRC) after disease progression remains to be determined. Patients and Methods: Readministration of anti-EGFR antibody in mCRC patients previously refractory to anti-EGFR antibody was prospectively observed. Results: A total of thirteen patients with a median age of 60-years old and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled. The median number of previous chemotherapies was 3 (range 2-5). Prior anti-EGFR antibody in combination with cytotoxic drugs was administered in 12 patients. Anti-EGFR antibody readministration regimens were cetuximab/panitumumab plus capecitabine/S-1 (seven patients), panitumumab plus FOLFOX (three patients), cetuximab plus irinotecan (two patients), and panitumumab monotherapy (one patient). Seven patients showed stable disease following readministration and six patients showed progressive disease. The median overall survival (OS) following readministration was 228 days and the median PFS was 102 days. Patients with intervals longer than 90 days between anti-EGFR therapies exhibited more favorable survival than those with intervals shorter than 90 days. Switching of anti-EGFR antibody between treatments was observed to contribute survival. Conclusion: Anti-EGFR antibody readministration could show a modest survival benefit in mCRC patients, with the length of therapy interval and switching of antibody being important contributory factors.

UR - http://www.scopus.com/inward/record.url?scp=85032146890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032146890&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12101

DO - 10.21873/anticanres.12101

M3 - Article

C2 - 29061833

AN - SCOPUS:85032146890

VL - 37

SP - 6459

EP - 6468

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -